From: An update on angiogenesis targeting in head and neck squamous cell carcinoma
AGENTS | STUDY DESIGN/PHASE | # of PATIENTS | PRIMARY ENDPOINT/OTHER EFFICACY ENDPOINTS | REFERENCE |
---|---|---|---|---|
Sorafenib | ||||
 Sorafenib 400 mg twice daily | Single arm, Phase II Single arm, Phase II | n = 41 n = 27 | RR 2%; median PFS 4 mo; median OS 9 mo RR 4%; median PFS 1.8 mo; median OS 4.2 mo | Williamson, 2010 [15] Elser, 2007 [16] |
Sunitinib | ||||
 Sunitinib 37.5 mg daily | Single arm, Phase II | n = 38 | Rate of disease control 50%; RR 3%; median PFS 2 mo; median OS 3.4 mo | Machiels, 2010 [17] |
 Sunitinib 50 mg daily for 4 weeks on, 2 weeks off | Single arm, Phase II (two cohorts, cohort A: PS 0–1 cohort B: PS 2) | n = 22 | Cohort A: RR 8%; median TTP 2 mo; median OS 4.9 mo Cohort B: RR 0; median TTP 2.5 mo; median OS 4.5 mo | Choong, 2010 [18] |
 Sunitinib 50 mg daily for 4 weeks on, 2 weeks off | Single arm, Phase II | n = 17 | RR 0; median TTP 2.3 mo; median OS 4 mo | Fountzilas, 2010 [19] |
Axitinib | ||||
 Axitinib 5 mg twice daily | Single arm, Phase II | n = 30 | 6-month PFS 30%; RR 7%; median PFS 3.7 months; median OS 10.9 mo | Swiecicki, 2015 [20] |
Combination Therapy | ||||
 Cetuximab +/− sorafenib | Randomized, Phase II | n = 55 | Median PFS 3 mo (cetuximab arm) and 3.2 mo (combination arm) | Gilbert, 2015 [21] |
 Docetaxel +/− vandetanib | Randomized, Phase II | n = 29 | RR 7% (docetaxel arm) and 13% (combination arm) | Limaye, 2013 [22] |
 Carboplatin, paclitaxel, sorafenib | Single arm, Phase II | n = 48 | Median PFS 8.5 mo; RR 55%; median OS 22.6 mo | Blumenschein, 2012 [23] |